What is malaria, including its definition, pathophysiology, clinical presentation, diagnosis, treatment, and prophylaxis?

Malaria: Comprehensive Overview

Definition

Malaria is a potentially life-threatening parasitic disease caused by protozoan parasites of the genus Plasmodium, transmitted primarily through the bite of infected female Anopheles mosquitoes 1. Five species commonly infect humans: P. falciparum, P. vivax, P. ovale (wallikeri and curtisi), P. malariae, and P. knowlesi 2. Less commonly, transmission occurs through blood transfusion or congenitally from mother to fetus 1.

Pathophysiology

The disease is characterized by fever secondary to the rupture of infected red blood cells, with macrophage ingestion of merozoites and release of tumor necrosis factor-α (TNF-α) 3. P. falciparum is the most dangerous species, capable of rapidly invading a high proportion of red blood cells and causing severe multi-organ disease including kidney failure, coma, and death 1, 2.

Clinical Presentation

Uncomplicated Malaria

The disease presents with non-specific "flu-like" symptoms 1:

• Fever (though not invariably present)
• Chills and sweats occurring at intervals
• Headache
• Myalgia and malaise
• Nausea, vomiting, diarrhea
• Cough

Associated findings include:

• Anemia
• Jaundice
• Thrombocytopenia
• Splenomegaly (often absent in early stages) 4

Critical pitfall: Malaria in children may present with misleading symptoms such as gastrointestinal features, sore throat, or lower respiratory complaints without typical fever patterns 5.

Severe Malaria

Severe malaria constitutes a medical emergency and is defined by vital organ involvement 6, 5:

Immediate life-threatening features:

• Depressed consciousness (any degree) or coma
• Active seizure activity
• Respiratory distress or hypoxia (oxygen saturation <95%)
• Shock (systolic BP <80 mmHg in adults, <70 mmHg if <1 year)
• Hypoglycemia (<3 mmol/L)
• Metabolic acidosis (base deficit >8 mmol/L)
• Severe anemia
• Acute kidney injury
• Pulmonary edema
• Significant bleeding/disseminated intravascular coagulation
• High parasitemia (>2% of red blood cells infected) 4, 5

Timing of Presentation

• P. falciparum: Rarely presents >6 months after exposure
• P. vivax, P. ovale, P. malariae: Can present >1 year after exposure, particularly if prophylaxis was taken 5

Diagnosis

When to Suspect Malaria

A diagnosis of malaria must always be sought in any febrile or sick patient who has visited malaria-endemic areas 5. This includes travelers returning from Central and South America, sub-Saharan Africa, Indian Subcontinent, Southeast Asia, Middle East, and Oceania 1.

Diagnostic Methods

Gold Standard:

• Thick and thin blood smears with Giemsa stain examined by an expert microscopist 7, 5
• Thick films detect parasites; thin films identify species
• The diagnosis cannot be excluded until more than one blood specimen has been examined 5

Rapid Diagnostic Tests (RDTs):

• Detect plasmodial antigens
• Highly reliable for P. falciparum and P. vivax
• Less reliable for other species 5
• Important adjunctive tool, especially in settings with limited microscopy expertise 8

Quality Control:

• When diagnoses are made by locally trained microscopists, randomly selected samples of both positive and negative slides should be sent to a reference laboratory for verification 7

Critical caveat: The presence of Plasmodium on blood smears does not prove malaria is the cause of febrile illness; other causes including pneumonia, meningitis, and viral hemorrhagic fevers must be considered 7, 5.

Treatment

Uncomplicated P. falciparum Malaria

For non-pregnant adults and children, artemisinin-based combination therapy (ACT) is first-line treatment 2, 5:

Preferred regimens:

• Artemether-lumefantrine (Riamet®) - drug of choice 5
• Dihydroartemisinin-piperaquine (Eurartesim®) - alternative 5

Alternative regimens when ACT unavailable:

• Atovaquone-proguanil (Malarone®)
• Quinine plus doxycycline (quinine is highly effective but poorly tolerated and requires combination therapy) 5

For chloroquine-sensitive regions (e.g., Haiti):

• Chloroquine remains an option for uncomplicated cases 6
• Adults: 600 mg, 600 mg, and 300 mg at 0,24, and 48 hours
• Children: 10 mg/kg, 10 mg/kg, and 5 mg/kg at 0,24, and 48 hours 7

Monitoring:

• Most patients should be admitted for at least 24 hours as deterioration can occur suddenly 5
• Monitor for clinical improvement and parasite clearance 2

Severe/Complicated Malaria

Intravenous artesunate is the treatment of choice for severe malaria in adults and children 2, 5. This represents a critical mortality-reducing intervention.

If artesunate unavailable:

• Start intravenous quinine immediately 5
• Requires careful monitoring for hypoglycemia
• Pregnant women receiving IV quinine need particularly close glucose monitoring 7

Management setting:

• High-dependency or intensive care unit
• May require hemodynamic support
• Management of acute respiratory distress syndrome, disseminated intravascular coagulation, acute kidney injury, seizures
• Children with severe malaria should receive empirical broad-spectrum antibiotics until bacterial infection excluded 5

Post-treatment monitoring:

• Check hemoglobin approximately 14 days after IV artesunate treatment, as hemolysis occurs in 10-15% of patients 5
• Parasitemia should be checked every 12 hours until <1%, then every 24 hours until negative 2
• Daily monitoring of full blood count, hepatic, renal, and metabolic parameters 2

Malaria in Pregnancy

Falciparum malaria in pregnancy is more likely to be complicated, with high placental parasite levels and risk of stillbirth or early delivery 5.

Second and third trimester:

• Artemether-lumefantrine for uncomplicated malaria 5
• Intravenous artesunate for severe malaria 5

First trimester:

• Quinine plus clindamycin for uncomplicated malaria (seek specialist advice) 5
• Intravenous artesunate for severe malaria (benefits outweigh risks) 5

Chloroquine is safe during pregnancy for chloroquine-sensitive infections 7.

Non-Falciparum Malaria (P. vivax, P. ovale, P. malariae, P. knowlesi)

Initial treatment:

• Either oral ACT or chloroquine 2, 5
• ACT preferred for mixed infections, uncertain species, or P. vivax from chloroquine-resistant areas 5

Hypnozoite eradication (P. vivax and P. ovale only):

• Primaquine is the only effective drug for eradicating dormant liver stages (hypnozoites) 2, 5
• Adults: 15 mg daily for 14 days 7
• Children: 0.3 mg/kg/day 7
• More effective when taken concurrently with chloroquine rather than sequentially 5
• Alternative: Tafenoquine (single dose) 2

Critical contraindications for primaquine:

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency - may cause severe hemolysis 5
• Pregnancy 5
• Breastfeeding (until G6PD status of infant known) 5
• Among Asian populations with severe G6PD deficiency, primaquine should not be given for >5 days 7

For pregnant women with P. vivax/P. ovale:

• Treat acute infection with chloroquine or ACT
• Give weekly chloroquine prophylaxis until delivery or cessation of breastfeeding
• Then administer primaquine for hypnozoite eradication 5

Pediatric Considerations

Uncomplicated malaria:

• ACT (artemether-lumefantrine or dihydroartemisinin-piperaquine) as first-line 5
• Alternatives: quinine with clindamycin (not doxycycline if <12 years), or atovaquone-proguanil at weight-appropriate doses 5

Severe malaria:

• Intravenous artesunate 5
• Empirical broad-spectrum antibiotics until bacterial infection excluded 5

Prophylaxis

Geographic Risk Assessment

Sub-Saharan Africa poses the highest risk: 80% of imported P. falciparum cases in U.S. civilians were acquired there, despite representing only a fraction of travelers compared to Asia and South America 1.

Chemoprophylaxis Options

For chloroquine-resistant P. falciparum areas (most malarious regions):

• Mefloquine - historically recommended as drug of choice 1
• Atovaquone-proguanil
• Doxycycline

For chloroquine-sensitive areas:

• Chloroquine 300 mg base weekly 9

In areas of limited to moderate chloroquine resistance:

• Chloroquine 300 mg weekly plus proguanil 200 mg daily provides substantial (though not complete) protection 9

Critical principle: No prophylactic agent prevents malaria 100%; prophylaxis must be augmented with personal protective measures 3.

Personal Protection Measures

Avoiding mosquito bites is fundamental 9:

• Sleep in properly screened rooms
• Use insecticide-impregnated bed nets (permethrin 0.2 g/m² every 6 months) 9
• Wear long-sleeved clothing and long trousers after sunset
• Apply diethyltoluamide (DEET) repellents to exposed skin (follow manufacturer's recommendations, especially for children) 9
• Use electric mats to vaporize synthetic pyrethroids or burn mosquito coils overnight 9
• Spray rooms with knockdown insecticide before evening 9

Electronic buzzers marketed as repellents are not effective 9.

Key Clinical Pitfalls

1. Delayed diagnosis is responsible for preventable deaths every year 2. Maintain high index of suspicion in any febrile traveler.

2. Fever is not invariably present - do not exclude malaria based on absence of fever alone 5.

3. Most imported malaria cases result from failure to take chemoprophylaxis: 71.7% of U.S. residents diagnosed with malaria had not taken prophylaxis during travel 6.

4. Chloroquine resistance is now widespread: Almost all sub-Saharan African countries have chloroquine-resistant P. falciparum 9. Do not use chloroquine monotherapy for P. falciparum except from known chloroquine-sensitive regions.

5. Mixed infections occur and commonly involve P. falciparum - treat as falciparum malaria with attendant precautions 5.

6. An acute attack does not confer protection - individuals who have had malaria require effective prophylaxis during future visits to endemic areas 5.

7. All febrile illness within one year of returning from malarious areas requires urgent investigation for malaria 9.

Drug Resistance Considerations

• Chloroquine resistance: Widespread in P. falciparum globally except limited areas (e.g., Haiti, Central America west of Panama Canal) 9, 6
• Mefloquine resistance: Problem in parts of Cambodia, Thailand, and Myanmar 9
• Emerging chloroquine-resistant P. vivax: Reported in Oceania 9

The mortality rate from malaria is approximately 0.3% in the U.S. and 0.26% worldwide, but delayed diagnosis and treatment significantly increase this risk 6.